Reopening Of Public Comment Period For Opioid Class REMS Confirms Long Road Ahead
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is reopening the public comment period for the class-wide opioid Risk Evaluation and Mitigation Strategy until Oct. 19, 2010.
You may also be interested in...
As Opioid REMS Meeting Nears, FDA Notes Worry About Shifting Use To Different Class
In NEJM editorial, FDA's Woodcock suggests "unintended consequences" of any risk management plan for the pain products.
As Opioid REMS Meeting Nears, FDA Notes Worry About Shifting Use To Different Class
In NEJM editorial, FDA's Woodcock suggests "unintended consequences" of any risk management plan for the pain products.
Opioid REMS Development Achieves Milestone: Another Public Meeting
FDA will meet with manufacturers on Dec. 4 to discuss progress on developing the safety program.